KEY POINTS:
Otago-based biotech firm Botry-Zen ended the six months to September 30 with a negative cashflow of more than $460,000.
The deficit was despite the biological control company raising $750,000 from the issue of nearly 19 million shares and receiving a $232,000 Trade and Enterprise grant.
